Inhibrx Biosciences (INBX) Stock Forecast & Price Target
Score
Inhibrx Biosciences Inc. price target
| INBX | |
|---|---|
| Low | $245.00 |
| Average | $285.00 |
| High | $325.00 |
| Upside vs current price | +242.1% |
The average target of $285.00 is +242.1% versus the current INBX price of $83.30.
Inhibrx Biosciences Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 0 |
| Buy | 3 |
| Hold | 1 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
4 analysts cover INBX.
Is Inhibrx Biosciences Inc. a buy or sell?
Of the 4 analysts covering Inhibrx Biosciences Inc., 3 rate it a buy (0 strong buy and 3 buy), 1 rates it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The INBX consensus label is Buy, beside 3 buy-side ratings and 0 sell-side ratings.
The average target of $285.00 implies +242.1% versus the current price of $83.30.
The INBX rating block is 4 published views with a Buy label. It does not tell you whether to buy or sell.
Reading the Inhibrx Biosciences Inc. forecast
the Inhibrx Biosciences Inc. is priced by the street between $245.00 and $325.00, average $285.00.
The gap from the $83.30 price to the INBX average is +242.1%.
The INBX rating mix is lopsided rather than split: 3 of 4 analysts are on the buy side, 1 is at hold, and 0 are on the sell side, and the published consensus is Buy.
With 4 analysts on INBX, the average is a small sample.
Inhibrx Biosciences Inc. forecast questions
What is the INBX price target?
The published range for INBX is $245.00 to $325.00, with an average of $285.00. That average is +242.1% versus the current price of $83.30.
Is Inhibrx Biosciences Inc. a buy or sell?
Of the 4 analysts covering Inhibrx Biosciences Inc., 3 rate it a buy, 1 rates it a hold, and 0 rate it a sell. The consensus is Buy, leaving INBX at 3 buy ratings, 1 holds, and 0 sells.
What is the EPS estimate for Inhibrx Biosciences Inc.?
No EPS estimate for the next two fiscal years is on file for Inhibrx Biosciences Inc..
What is the revenue estimate for Inhibrx Biosciences Inc.?
No revenue estimate for the next two fiscal years is on file for Inhibrx Biosciences Inc..
How many analysts cover INBX?
4 analysts cover INBX. Their consensus on INBX is Buy, across those 4.